Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors.

Nonetheless, though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck is also working on different strategies to drive Keytruda's long-term ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

RAHWAY, N.J., May 31, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...

Key Takeaways Evorpacept and Keytruda combination failed to meet primary endpoints in ASPEN-03 and ASPEN-04 trials for advanced HNSCC. The combination did not improve objective response rates compared ...

Your Keytruda treatment may last for around 2 years, but certain factors may mean that you’ll receive the drug for a longer or shorter time. If you have questions about what to expect from your ...

Keytruda belongs to a class of medications called programmed death receptor-1 blocking antibodies (PD1-blocking antibodies). These drugs work by binding to certain parts of cells. This action ...

The Keytruda market is expected to grow strongly even beyond that point, namely to $45.9 billion by 2032, at a CAGR of 9.20%. Keytruda market projections (Market Research Future) ...

The half-life of Keytruda’s active ingredient, pembrolizumab, is around 22 days. (A drug’s half-life is the amount of time it takes for your body to get rid of half a dose.) ...

The Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) plus pemetrexed and platinum chemotherapy for the first-line treatment of patients with unresectable advanced or metastatic ...